

# Technical Information Report

AAMI TIR23:  
1999/(R)2019

Signal averaging

## Signal averaging

Approved 15 March 1999 and reaffirmed 19 September 2019 by  
AAMI

**Abstract:** The signal-averaged electrocardiogram (SAECG) facilitates noninvasive recording of low-amplitude cardiac signals such as ventricular late potentials. The SAECG has been used to predict life-threatening ventricular tachyarrhythmias in patients after acute myocardial infarction and with nonischemic dilated cardiomyopathy and to screen for inducible ventricular tachycardia in patients with unexplained syncope and with nonsustained ventricular tachycardia. This technical information report focuses on currently accepted methodology and clinical applications of the SAECG.

**Key words:** signal-averaged electrocardiogram (ECG), ventricular tachycardia, sudden cardiac death, electrophysiologic study, syncope, myocardial infarction, cardiomyopathy, atrial fibrillation

*Published by*

AAMI  
901 N. Glebe Road, Suite 300  
Arlington, VA 22203

Copyright © 2000 by the Association for the Advancement of Medical Instrumentation

All rights reserved.

Publication, reproduction, photocopying, storage or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI at 901 N. Glebe Road, Suite 300, Arlington, VA 22203. Phone:(703) 525-4890, Ext. 239; Fax: (703) 525-0600.

Printed in the United States of America

ISBN 1-57020-129-3

---

## AAMI TECHNICAL INFORMATION REPORT

---

A Technical Information Report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, there is value in releasing the information because of the immediate need for it by the industry and the professions.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences among these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that although both standards and TIRs are periodically reviewed, a standard must be acted upon—either reaffirmed, revised, or withdrawn—and the action formally approved usually every 5 years but at least every 10 years. For a TIR, AAMI consults with a technical committee about 5 years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

**CAUTION NOTICE:** This AAMI Technical Information Report may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

# Contents

	Page
Committee representation .....	vi
<b>1</b> Scope.....	1
<b>2</b> Definitions .....	1
<b>3</b> State of the art of current SAECG device design .....	3
<b>3.1</b> Introduction.....	3
<b>3.2</b> Architecture.....	3
<b>3.3</b> Comparative table of specifications.....	4
<b>3.4</b> Summary of beat alignment and measurement methods .....	5
<b>4</b> Selection and alignment of normal sinus rhythm beats for ensemble averaging .....	5
<b>4.1</b> Overview.....	5
<b>4.2</b> Selecting a normal sinus rhythm beat as a “template” .....	5
<b>4.3</b> Beat alignment techniques .....	6
<b>4.4</b> Rejecting nonsinus rhythm beats .....	6
<b>5</b> Ensemble averaging.....	6
<b>5.1</b> Overview.....	6
<b>5.2</b> Endpoint of signal averaging: quality control.....	7
<b>5.3</b> Rejection of adversely noisy beats .....	7
<b>6</b> SAECG analysis: digital filtering, lead combination, and measurements .....	7
<b>6.1</b> Overview.....	7
<b>6.2</b> Digital filtering schemes.....	8
<b>6.3</b> Butterworth IIR filter, applied in a bidirectional mode.....	8
<b>6.4</b> Spectral window filter.....	8
<b>6.5</b> FIR filter .....	8
<b>6.6</b> Lead combination: vector magnitude waveform.....	8
<b>6.7</b> SAECG measurements of late potentials .....	9
<b>7</b> Clinical applications of SAECG .....	9
<b>7.1</b> SAECG methodology .....	9
<b>7.2</b> Clinical application of the SAECG .....	11
<b>7.2.1</b> PredischARGE risk stratification after acute MI.....	11
<b>7.2.2</b> Using the SAECG in combination with other noninvasive test results to predict serious ventricular arrhythmias after MI.....	12
<b>7.2.3</b> Clinical indications of the SAECG after MI .....	13
<b>7.2.4</b> Interaction of invasive risk stratification with programmed ventricular stimulation and the SAECG .....	15
<b>7.2.5</b> The clinical utility of the SAECG in the thrombolytic era.....	16
<b>7.2.6</b> Prognostic value of the SAECG in patients with idiopathic dilated cardiomyopathy or with advanced heart failure.....	18
<b>7.2.7</b> Predicting electrically induced ventricular tachycardia in the electrophysiology laboratory of patients with unexplained syncope.....	20
<b>7.2.8</b> Predicting inducibility of sustained VT in patients with nonsustained VT .....	21
<b>8</b> Emerging areas in signal-averaged ECG.....	22
<b>8.1</b> Frequency domain analysis.....	22
<b>8.2</b> P-wave signal averaging and analysis methods .....	22
<b>8.3</b> Application of P-SAECG to measurement of atrial activation.....	23
<b>Annexes</b>	
<b>A</b> Cited references .....	24
<b>B</b> Bibliography .....	30

**Tables**

1 Estimated value of the signal-averaged ECG combined with other noninvasive variables for predicting serious arrhythmic events after myocardial infarction ..... 14

2 Prognostic value of the post-MI SAECG in the thrombolytic era ..... 17

**Figures**

1 Representative architecture of current SAECG devices ..... 3

2 The process of signal-averaged ECG recording and analysis ..... 11

3 Odd ratios for risk of arrhythmic event after MI ..... 4

4 Plot of the proportional distribution of patients relative to filtered QRS (fQRS) duration according to treatment assignment in randomized trial of late thrombolytic therapy ..... 16

5 Survival curves displaying freedom from death or sustained ventricular arrhythmia in heart failure patients with normal or abnormal signal-averaged (SA) ECG and bundle branch block ..... 19

6 Prediction of inducible ventricular tachycardia in patients with unexplained syncope, based on presence of single or combination noninvasive variables ..... 21

## Committee representation

### Association for the Advancement of Medical Instrumentation Electrocardiograph Committee

This technical information report (TIR) was developed by the ECG/Signal Averaging Working Group of the AAMI Electrocardiograph Committee. Committee approval of the TIR does not necessarily imply that all committee members voted for its approval.

At the time this document was balloted, the **AAMI Electrocardiograph Committee** had the following members:

*Cochairs:* James J. Bailey, MD  
David Mortara, PhD

*Members:* James J. Bailey, MD, National Institutes of Health  
Alan S. Berson, PhD, National Heart, Lung, and Blood Institute  
Robert E. Bruce, Medicomp  
David Daly, U.S. Food and Drug Administration  
Arthur R. Eddy, Jr., ConMed Corp.  
Stacy Gehman, Quinton Instrument Co.  
Paul Lander, University of Oklahoma Health Sciences Center  
George Moody, Massachusetts Institute of Technology  
David Mortara, PhD, Mortara Instrument Inc.  
Shankara Reddy, PhD, GE-Marquette Medical Systems  
William Saltzstein, Medtronic Physio-Control Corp.  
Jonathan Steinberg, MD, St. Luke's Roosevelt Hospital  
Roy D. Wallen, Pure Pulse Technologies

*Alternates:* Robert J. Cangelosi, U.S. Food and Drug Administration

At the time this document was balloted, the committee's **ECG Signal Averaging Working Group** had the following members:

*Cochairs:* Paul Lander  
William Saltzstein  
Jonathan Steinberg, MD

*Members:* Edward J. Berbari, PhD, Indiana University  
Alan Berson, PhD, National Heart, Lung, and Blood Institute  
Stacy Gehman, Quinton Instrument Company  
Paul Lander, University of Oklahoma Health Sciences Center  
Shankara Reddy, PhD, GE-Marquette Medical Systems  
William Saltzstein, Medtronic Physio-Control Corp.  
Craig Sellers, Spacelabs Burdick  
Mike Simson, MD, University of Pennsylvania  
Jonathan Steinberg, MD, St. Luke's Roosevelt Hospital  
Terry Sweeten, Plastics One Inc.  
Sandy Weininger, U.S. Food and Drug Administration

*Alternates:* Carole Carey, U.S. Food and Drug Administration

### Acknowledgement

The ECG Signal Averaging Working Group gratefully acknowledges the contributions of former cochair Edward Berbari, PhD, and contributor Eric Chan, PhD.

---

NOTE—Participation by federal agency representatives in the development of this report does not constitute endorsement by the federal government or any of its agencies.

---

---

---

# Signal averaging

## 1 Scope

Signal averaging of the electrocardiogram (SAECG) was devised 25 years ago to reveal low-amplitude cardiac signals in the microvolt range on the body surface. It was originally used to detect His-Purkinje activity (A.1). However, in the next decade the methods for SAECG were refined and developed to determine the full extent of ventricular activation with the object of revealing delays relating to electrical instability of the ventricular myocardium.

The purpose of this report is to provide an understanding of the fundamental principles underlying SAECG methodology, to define terminology, and to review its potential for clinical application. It includes a discussion of some of the major pitfalls that must be avoided. This report is directed partly to those who have an interest in the clinical use of the SAECG but also to those who are considering the development of SAECG methodology in a medical device. The following topics are covered:

- a) device architecture for data acquisition and processing;
- b) beat selection and alignment;
- c) ensemble averaging;
- d) filtering, lead combination, and measurement;
- e) clinical applications and emerging uses;
- f) a list of publications for further reference;
- g) terminology.

## 2 Definitions

For the purposes of this technical information report, the following definitions apply.

**2.1 bandpass filter:** A filter that will pass frequencies within a desired range but will attenuate all other frequencies (e.g., a 40– to 250–Hz filter would attenuate frequencies below 40 Hz and above 250 Hz).

**2.2 baud rate:** The number of bits per second that can be transmitted in a given computer system.

NOTE—When information is transmitted between two computer systems, each must be set to the same baud rate.

**2.3 bidirectional filter:** A type of digital filter that filters the signal in a forward direction from its beginning to its midpoint and then filters from the end of the signal in a backward direction to the same midpoint.

**2.4 Butterworth amplitude filter:** A type of filter known for its filter quality on small signals; the filter of choice for the vector magnitude and late potential detection.

**2.5 corner frequency:** The frequency or frequencies selected to define a filter band (e.g., 40– to 250–Hz Butterworth filter).

**2.6 FFT:** Fast Fourier Transform is a method by which a segment of time series data can be evaluated for its frequency components.

**2.7 fiducial point:** A reliable, stable reference point that allows multiple beats to be aligned for averaging.

NOTE—The fiducial point commonly used for SAECGs is the onset of the QRS or the time of maximum slope of the QRS.

**2.8 filter:** A device or software algorithm that passes information within signals of certain frequencies or frequency ranges while attenuating others.

**2.9 finite impulse response (FIR) filter:** A type of filter that relies only on previous input to generate its present output.

**2.10 high pass filter:** A filter that attenuates frequencies below a specified frequency (e.g., a 40–Hz high pass filter would attenuate all frequencies below 40 Hz).